Financials data is unavailable for this security.
View more
Year on year iSpecimen Inc 's revenues fell -4.56%from 10.40m to 9.93m. In addition, the company has been unable to reduce the cost of goods sold, selling, general and administrative expenses and interest paid (all as a percentage of sales). This has contributed to a 8.33% reduction in net income from a loss of 10.25m to a larger loss of 11.10m.
Gross margin | 50.08% |
---|---|
Net profit margin | -97.04% |
Operating margin | -97.53% |
Return on assets | -69.19% |
---|---|
Return on equity | -98.03% |
Return on investment | -98.03% |
More ▼
Cash flow in USDView more
In 2023, cash reserves at iSpecimen Inc fell by 12.97m. Cash Flow from Financing totalled 70.89k or 0.71% of revenues. In addition the company used 5.81m for operations while cash used for investing totalled 7.23m.
Cash flow per share | -16.34 |
---|---|
Price/Cash flow per share | -- |
Book value per share | 9.30 |
---|---|
Tangible book value per share | -0.6389 |
More ▼
Balance sheet in USDView more
Current ratio | 0.9007 |
---|---|
Quick ratio | -- |
Total debt/total equity | 0.00 |
---|---|
Total debt/total capital | 0.00 |
More ▼